Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly
Tout savoir sur le treat and extend : organisation et optimisation. Les Cahiers d'Ophtalmologie
2019La dégénérescence maculaire liée à l’âge (DMLA) est actuellement la première cause de handicap visuel dans les pays développés chez les plus de 50 ans. Elle touche en effet environ 8% de la population française et plus de 25% des plus de 75 ans. La constatation d’une insuffisance de traitement lors d’un régime « réactif » a poussé les cliniciens à ...
Carré, Chloé +2 more
openaire +1 more source
Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration
Ophthalmology Retina, 2018Hidetaka Matsumoto +4 more
openaire +1 more source
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Nature Reviews Drug Discovery, 2021Kamakoti P Bhat, Jian Jin, Or Gozani
exaly
Neovaskuläre altersbedingte Makuladegeneration – IVOM: Weniger Arztbesuche durch Treat and Extend?
Klinische Monatsblätter für Augenheilkunde, 2016openaire +1 more source
Modulating gene regulation to treat genetic disorders
Nature Reviews Drug Discovery, 2020Navneet Matharu, Nadav Ahituv
exaly
Letter to the Editor: Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion
Ophthalmic Surgery, Lasers and Imaging Retina, 2015Dan, Călugăru, Mihai, Călugăru
openaire +2 more sources
Treat and Extend Analysis Trial With Aflibercept in Wet-AMD
Case Medical Research, 2019openaire +1 more source
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology, 2010Omesh P. Gupta +5 more
openaire +1 more source